Aim Immunotech Story

All StoriesHype
Raphi Shpitalnik Story
<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:4em;'>AI</div>
AIM -- USA Stock  

USD 2.15  0.03  1.38%

Macroaxis News
By Raphi Shpitalnik  
Macroaxis Story
In general, we focus on analyzing Aim Immunotech (NYSEMKT:AIM) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aim Immunotech daily price indicators and compare them against related drivers. Let's first try to summarize why Aim Immunotech investors are seeking stability amid unprecedented economic uncertainty.
Published over a month ago
View all stories for Aim Immunotech | View All Stories
Chances of Aim Immunotech (NYSEMKT:AIM) to pull down in December.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aim Immunotech has an asset utilization ratio of 0.73 percent. This denotes that the company is making $0.007332 for each dollar of assets. An increasing asset utilization means that Aim Immunotech is more efficient with each dollar of assets it utilizes for everyday operations.
The successful prediction of Aim Immunotech stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Aim Immunotech, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Aim Immunotech based on Aim Immunotech hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Aim Immunotech's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Aim Immunotech's related companies.

Use Technical Analysis to project Aim Immunotech expected Price

Aim Immunotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Overlap Analysis
View
Forecast Models
View
Price Shifting
View
Volatility Indicators
View
Value Movement
View
A focus of Aim Immunotech technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Aim Immunotech trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Aim Immunotech utilizes its cash?

To perform a cash flow analysis of Aim Immunotech, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Aim Immunotech is receiving and how much cash it distributes out in a given period. The Aim Immunotech cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Aim Immunotech Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (11.25 Million)

Breaking down the case for Aim Immunotech

The company reported the last year's revenue of 171 K. Reported Net Loss for the year was (11.66 M) with loss before taxes, overhead, and interest of (753 K).

Cost of Revenue Breakdown

Aim Immunotech Cost of Revenue yearly trend continues to be relatively stable with very little volatility. Cost of Revenue may rise above about 971.7 K this year. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Aim Immunotech Cost of Revenue is relatively stable at the moment as compared to the past year. The company's current value of Cost of Revenue is estimated at 971,742
2013
2014
2015
2016
2017
2018
2019
2020
20131.23 Million
20141.25 Million
20151.6 Million
20161.11 Million
20171.18 Million
2018884,000
2019893,000
2020971,742

Over 3 percent hike for Aim Immunotech. What does it mean for stakeholders?

The jensen alpha is down to -0.19 as of today. Aim Immunotech exhibits very low volatility with skewness of 1.33 and kurtosis of 4.9. However, we advise investors to further study Aim Immunotech technical indicators to make sure all market info is available and is reliable.

Our Conclusion on Aim Immunotech

While some other companies within the biotechnology industry are still a little expensive, even after the recent corrections, Aim Immunotech may offer a potential longer-term growth to stakeholders. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither take over new shares of Aim Immunotech nor drop your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Aim Immunotech.

About Contributor

Raphi Shpitalnik is a Junior Member of Macroaxs Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time base at the beginning of the pandemic and eventually acquired a real test for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Aim Immunotech. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
Macroaxis Wealth Optimization Platform
 
Feedback Blog
Made with optimal in San Francisco
2021 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY